Hims & Hers Health (NYSE:HIMS) to Repurchase $250.00 million in Stock

Hims & Hers Health (NYSE:HIMS) declared that its Board of Directors has authorized a stock buyback program on Monday, November 17th, RTT News reports. The company plans to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Stock Performance

HIMS opened at $35.81 on Thursday. The firm has a fifty day moving average price of $49.88 and a 200 day moving average price of $51.31. Hims & Hers Health has a 1 year low of $21.36 and a 1 year high of $72.98. The stock has a market cap of $8.15 billion, a P/E ratio of 66.31, a P/E/G ratio of 7.22 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm’s quarterly revenue was up 49.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 EPS. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $45.27.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the sale, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total value of $6,852,231.96. Following the transaction, the chief executive officer owned 160,425 shares in the company, valued at $8,579,529. This trade represents a 44.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 630,583 shares of company stock worth $33,544,943 in the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.